Sector Chart Arcus Biosciences, Inc.

Stocks

RCUS

US03969F1093

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 20:46:00 19/08/2026 BST			5-day change	1st Jan Change
30.38 ^USD	+2.95%		+5.63%	+28.37%

08-10	Arcus Biosciences' Casdatifan Therapy Could be Launched in 2028, Morgan Stanley Says	MT
08-10	Morgan Stanley Adjusts Price Target on Arcus Biosciences to $23 From $22, Maintains Equalweight Rating	MT

Total Return

"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes

Sector Other Biotechnology & Medical Research

	Capi.	Sales Growth	Profitability	Finances	EV / Sales	P/E
ARCUS BIOSCIENCES, INC.	3.76B					-
LONZA GROUP AG	48.63B
REVOLUTION MEDICINES, INC.	46.3B	-	-	-	-	-
BEONE MEDICINES AG	41.97B
IQVIA HOLDINGS INC.	39.51B
CELLTRION, INC.	31.75B